Paper Details

  1. Home
  2. Paper Details

Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects.

Author: AkmanLevent, AkmanTulay, ErbasOytun, YilmazAhmet U

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pazopanib (PZP) is a tyrosine kinase inhibitor that can prolong the QT interval, increasing the risk of dangerous heart rhythm problems. This study found that metoprolol and diltiazem effectively prevented PZP-induced QT prolongation in rats, suggesting these drugs may be a promising preventative strategy for people taking PZP.
Paper Details　
Original Abstract of the Article :
Background: Pazopanib (PZP) may induce prolonged cardiac repolarization and proarrhythmic effects, similarly to other tyrosine kinase inhibitors. Objectives: To demonstrate PZP-induced prolonged cardiac repolarization and proarrhythmic electrophysiological effects and to investigate possible prevent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262101/

データ提供：米国国立医学図書館（NLM）

Pazopanib: Navigating Cardiac Risks in Cancer Treatment

Pazopanib (PZP) is a tyrosine kinase inhibitor used to treat various cancers. However, it can induce prolonged cardiac repolarization and proarrhythmic effects. This study investigated the potential of metoprolol and diltiazem to prevent PZP-induced prolonged cardiac repolarization in an experimental rat model. The study found that both metoprolol and diltiazem significantly shortened the QTc interval, a measure of cardiac repolarization, in rats treated with PZP. The study suggests that these drugs may offer a promising prophylactic strategy for preventing PZP-induced QT interval prolongation.

Managing Cardiac Risks with Pazopanib

This study provides insights into managing the cardiac risks associated with PZP treatment. The researchers found that metoprolol and diltiazem effectively prevented PZP-induced QT interval prolongation. This finding is significant, as it suggests that these drugs could help to minimize the cardiac risks associated with PZP therapy. This research offers hope for patients undergoing PZP treatment.

Finding a Safe Path in the Desert of Cancer Treatment

This research offers a valuable solution for managing the cardiac risks associated with PZP treatment. The study suggests that metoprolol and diltiazem could help to prevent PZP-induced QT interval prolongation, ensuring a safer treatment journey for cancer patients. It's like finding a safe path in the desert of cancer treatment, avoiding potential pitfalls and ensuring a smooth and safe journey.

Dr. Camel's Conclusion

This study suggests that metoprolol and diltiazem can effectively prevent PZP-induced QT interval prolongation. This research offers hope for patients undergoing PZP treatment and contributes to the ongoing quest for safer and more effective cancer therapies.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

25229355

DOI: Digital Object Identifier

PMC4262101

Related Literature

Article Analysis
・Effects of pazopanib
SNS
PICO Info
in preparation
Languages

Portuguese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.